Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,610 · see citing works

The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060 · see citing works

EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity

Bieschke, J., Russ, J., Friedrich, R., Ehrnhoefer, D. E., Wobst, H. J., Neugebauer, K., & Wanker, E. (2010) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0910723107 · Cited by 986 · see citing works

Cannabidiol and (−)Δ ⁹ -tetrahydrocannabinol are neuroprotective antioxidants

Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · see citing works

Mechanism of thioflavin T binding to amyloid fibrils

Khurana, R., Coleman, C., Ionescu‐Zanetti, C., Carter, S. A., Krishna, V., Grover, R. K., Roy, R., & Singh, S. S. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.06.006 · Cited by 833 · see citing works

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & CEBALLOS, M. L. D. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 783 · see citing works

Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders

Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622 · see citing works

The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds

Hudson, S. A., Ecroyd, H. W., Kee, T. W., & Carver, J. A. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07307.x · Cited by 614 · see citing works

Role of toll-like receptor signalling in A uptake and clearance

Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493 · see citing works

Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide

Hu, X., Crick, S. L., Bu, G., Frieden, C., Pappu, R. V., & Lee, J.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911281106 · Cited by 426 · see citing works

Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement

Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · see citing works

Neuroprotective effect of cannabidiol, a non‐psychoactive component from<i>Cannabis sativa</i>, on β‐amyloid‐induced toxicity in PC12 cells

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361 · see citing works

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Fernández‐Ruíz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R. G., Mechoulam, R., & Martínez-Orgado, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 356 · see citing works

N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor

McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323 · see citing works

Cannabidiol <i>in vivo</i> blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression

Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308 · see citing works

Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid Aβ into Off-pathway Conformers

Ladiwala, A. R. A., Lin, J. C., Bale, S. S., Marcelino, A. M. C., Bhattacharya, M., Dordick, J. S., & Tessier, P. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.133108 · Cited by 299 · see citing works

Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer’s disease

Pan, X.-D., Zhu, Y.-G., Lin, N., Zhang, J., Ye, Q.-Y., Huang, H.-P., & Chen, X.-C. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-45 · Cited by 292 · see citing works

Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease

Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y., Teng, Z., & Chen, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.030 · Cited by 272 · see citing works

Endocannabinoid signaling in microglial cells

Stella, N. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.037 · Cited by 271 · see citing works

Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels

Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 258 · see citing works

Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition

Langer, F., Eisele, Y. S., Fritschi, S. K., Staufenbiel, M., Walker, L. C., & Jucker, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3088-11.2011 · Cited by 237 · see citing works

Cannabinoid activation of PPARα; a novel neuroprotective mechanism

Sun, Y., Alexander, S. P. H., Garle, M. J., Gibson, C. L., Hewitt, K. N., Murphy, S. P., Kendall, D. A., & Bennett, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707478 · Cited by 229 · see citing works

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement

Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225 · see citing works

A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease

Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223 · see citing works

CB 1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition

Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A. G., & Shohami, E. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600047 · Cited by 180 · see citing works

Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide

Espuny-Camacho, I., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D. I., & Strooper, B. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 169 · see citing works

Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2

McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G., & Ross, R. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.041863 · Cited by 131 · see citing works

Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide

Milton, N. G. N. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00936-9 · Cited by 124 · see citing works

Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults

Chen, X., Zhang, J., & Chen, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.01.024 · Cited by 123 · see citing works

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment

Schicho, R., Bashashati, M., Bawa, M., McHugh, D., Saur, D., Hu, H., Zimmer, A., Lutz, B., Mackie, K., Bradshaw, H. B., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21538 · Cited by 109 · see citing works

The endocannabinoid system as a target for the treatment of neuronal damage

Fernández‐Ruíz, J., García, C., Sagredo, O., Gómez‐Ruíz, M., & de Lago, E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003709792 · Cited by 89 · see citing works

2‐Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal‐cannabidiol‐sensitive receptors on microglial cells

Kreutz, S., Koch, M., Böttger, C., Ghadban, C., Korf, H., & Dehghani, F. (2008) · Glia · doi:10.1002/glia.20756 · Cited by 87 · see citing works

Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro

Harvey, B. S., Ohlsson, K. S., Mååg, J. L. V., Musgrave, I. F., & Smid, S. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.015 · Cited by 82 · see citing works

The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses

Bisogno, T., & Marzo, V. D. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785740027 · Cited by 80 · see citing works

The monoacylglycerol lipase inhibitor JZL 184 attenuates LPS ‐induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action

Kerr, D., Harhen, B., Okine, B. N., Egan, L. J., Finn, D. P., & Roche, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02237.x · Cited by 77 · see citing works

Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia

Egger, T., Schuligoi, R., Wintersperger, A., Amann, R., Malle, E., & Sattler, W. (2003) · Biochemical Journal · doi:10.1042/bj20021358 · Cited by 72 · see citing works

Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood–brain barrier damage

Hooper, C., Pinteaux‐Jones, F., Fry, V. A. H., Sevastou, I. G., Baker, D., Heales, S., & Pocock, J. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05953.x · Cited by 65 · see citing works

Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity

Cordier-Dirikoc, S., Priola, S. A., Marella, M., Zsürger, N., & Chabry, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1942-07.2007 · Cited by 63 · see citing works

Differential toxicity, conformation and morphology of typical initial aggregation states of Aβ1-42 and Aβpy3-42 beta-amyloids

Galante, D., Corsaro, A., Florio, T., Vella, S., Pagano, A., Sbrana, F., Vassalli, M., Perico, A., & D’Arrigo, C. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.010 · Cited by 51 · see citing works

Targeting the Endocannabinoid System in Alzheimer's Disease

Koppel, J. L., & Davies, P. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15315 · Cited by 50 · see citing works

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

Karl, T., Cheng, D., Garner, B., & Arnold, J. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.671812 · Cited by 50 · see citing works

Cannabinoids Inhibit Migration of Microglial-like Cells to the HIV Protein Tat

Fraga, D., Raborn, E. S., Ferreira, G. A., & Cabral, G. A. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9291-6 · Cited by 49 · see citing works

The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro

Harvey, B. S., Musgrave, I., Ohlsson, K. S., Fransson, A., & Smid, S. D. (2011) · Food Chemistry · doi:10.1016/j.foodchem.2011.06.040 · Cited by 41 · see citing works

Differentiation Increases the Resistance of Neuronal Cells to Amyloid Toxicity

Cecchi, C., Pensalfini, A., Liguri, G., Baglioni, S., Fiorillo, C., Guadagna, S., Zampagni, M., Formigli, L., Nosi, D., & Stefani, M. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9627-7 · Cited by 31 · see citing works

The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System

Ashton, J. C. (2012) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152412802430156 · Cited by 28 · see citing works

Replicating neuroblastoma cells in different cell cycle phases display different vulnerability to amyloid toxicity

Cecchi, C., Pensalfini, A., Stefani, M., Baglioni, S., Fiorillo, C., Cappadona, S., Caporale, R., Nosi, D., Ruggiero, M., & Liguri, G. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0265-3 · Cited by 24 · see citing works

The effects of pH and temperature on the in vitro bindings of delta-9-tetrahydrocannabinol and other cannabinoids to bovine serum albumin

Papa, V. M., Shen, M.-L., & Ou, D. W. (1990) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(90)80049-u · Cited by 8 · see citing works

Cannabidiol, neuroprotection and neuropsychiatric disorders

Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446 · see citing works

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer

Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., & Corsi, L. (2018) · BioMed Research International · doi:10.1155/2018/1691428 · Cited by 375 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age

Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic

Aso, E., & Ferrer, I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00037 · Cited by 244 · see citing works

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease

Watt, G., & Karl, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00020 · Cited by 227 · see citing works

Endocannabinoid system in neurodegenerative disorders

Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14098 · Cited by 212 · see citing works

Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders

Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease

Aso, E., & Ferrer, I. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00243 · Cited by 131 · see citing works

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Aymerich, M. S., Aso, E., Abellanas, M. A., Tolón, R. M., Ramos, J. A., Ferrer, I., Romero, J., & Fernández‐Ruíz, J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.016 · Cited by 110 · see citing works

The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer's Disease

Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., & Gaetani, S. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141635 · Cited by 104 · see citing works

Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy

Abate, G., Uberti, D. L., & Tambaro, S. (2021) · Biology · doi:10.3390/biology10060542 · Cited by 101 · see citing works

Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease

Schubert, D. A., Kepchia, D., Liang, Z., Dargusch, R., Goldberg, J., & Maher, P. A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1637-8 · Cited by 92 · see citing works

Dietary Polyphenols: A Multifactorial Strategy to Target Alzheimer’s Disease

Dhakal, S., Kushairi, N., Phan, C., Adhikari, B., Sabaratnam, V., & Macreadie, I. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205090 · Cited by 89 · see citing works

A Neuron, Microglia, and Astrocyte Triple Co-culture Model to Study Alzheimer’s Disease

Luchena, C., Zuazo-Ibarra, J., Valero, J., Matute, C., Alberdi, E. M., & Capetillo‐Zarate, E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.844534 · Cited by 82 · see citing works

Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway

Gugliandolo, A., Pollastro, F., Bramanti, P., & Mazzon, E. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104553 · Cited by 82 · see citing works

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease

Karl, T., Garner, B., & Cheng, D. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000247 · Cited by 78 · see citing works

Fatty acids, endocannabinoids and inflammation

Witkamp, R. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.051 · Cited by 76 · see citing works

Imaging Neuroinflammation in Neurodegenerative Disorders

Masdeu, J. C., Pascual, B., & Fujita, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263200 · Cited by 76 · see citing works

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets

Vitale, R. M., Iannotti, F. A., & Amodeo, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094876 · Cited by 74 · see citing works

Type-2 cannabinoid receptors in neurodegeneration

Bisogno, T., Oddi, S., Piccoli, A., Fazio, D., & Maccarrone, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.021 · Cited by 71 · see citing works

Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses

Chiurchiù, V., Leuti, A., & Maccarrone, M. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9584-2 · Cited by 68 · see citing works

Cordycepin Modulates Microglial M2 Polarization Coupled with Mitochondrial Metabolic Reprogramming by Targeting HKII and PDK2

Zhong, X., Gong, S., Meng, L., Yao, W., Du, K., Jiao, L., Ma, G., Liang, J., Wei, B., Jin, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202304687 · Cited by 69 · see citing works

Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation

Hill, J. D., Zuluaga‐Ramirez, V., Gajghate, S., Winfield, M., Sriram, U., Rom, S., & Persidsky, Y. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.11.017 · Cited by 66 · see citing works

Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action

Ożarowski, M., Karpiński, T. M. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094294 · Cited by 69 · see citing works

Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer's mice uncovered by RNA-seq

Hao, F., & Feng, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118624 · Cited by 64 · see citing works

Can We Treat Neuroinflammation in Alzheimer’s Disease?

Sánchez‐Sarasúa, S., Fernández-Pérez, I., Espinosa‐Fernández, V., Sánchez‐Pérez, A. M., & Ledesma, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228751 · Cited by 62 · see citing works

Cannabidiol protects against Alzheimer's disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups

Zhang, Y., Li, H., Jin, S., Lu, Y., Peng, Y., Zhao, L., & Wang, X. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174829 · Cited by 58 · see citing works

Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils

Komarnytsky, S., Thirumurugan, R., Wagner, C., Metzger, B. T., Carlisle, C., Panda, C., Brun-Blashka, S. L., TROUP, J. P., & Varadharaj, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115479 · Cited by 58 · see citing works

Cannabinoids for the treatment of dementia

Kuharić, D. B., Marković, D., Brković, T., Kegalj, M. J., Rubić, Ž., Vuica, A., Jerončić, A., & Puljak, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820.pub2 · Cited by 55 · see citing works

Clinical studies and anti‐inflammatory mechanisms of treatments

French, J. A., Koepp, M. J., Naegelin, Y., Vigevano, F., Auvin, S., Rho, J. M., Rosenberg, E. C., Devinsky, O., Olofsson, P. S., & Dichter, M. A. (2017) · Epilepsia · doi:10.1111/epi.13779 · Cited by 54 · see citing works

Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment

Montanari, S., Mahmoud, A. M., Pruccoli, L., Rabbito, A., Naldi, M., Petralla, S., Moraleda, I., Bartolini, M., Monti, B., Iriepa, I., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.080 · Cited by 54 · see citing works

Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells

Raja, A., Ahmadi, S., de Costa, F., Li, N., & Kerman, K. (2020) · Pharmaceuticals · doi:10.3390/ph13110328 · Cited by 52 · see citing works

Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia

Ferreira‐Junior, N. C., Pereira, M. D. S., Guimarães, F. S., & Bel, E. D. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00109-8 · Cited by 50 · see citing works

Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity

Das, S., Stark, L., Musgrave, I., Pukala, T. L., & Smid, S. D. (2016) · Food & Function · doi:10.1039/c5fo01281c · Cited by 46 · see citing works

Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 45 · see citing works

Altered Neurochemistry in Alzheimer’s Disease: Targeting Neurotransmitter Receptor Mechanisms and Therapeutic Strategy

Kaur, S., DasGupta, G., & Singh, S. (2019) · Neurophysiology · doi:10.1007/s11062-019-09823-7 · Cited by 45 · see citing works

Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer’s Disease

Amandine, E. B., & Marchalant, Y. (2015) · Aging and Disease · doi:10.14336/ad.2015.0617 · Cited by 43 · see citing works

Mechanistic insights into the potential role of dietary polyphenols and their nanoformulation in the management of Alzheimer’s disease

Albadrani, H. M., Chauhan, P., Ashique, S., Babu, M. A., Iqbal, D., Almutary, A. G., Abomughaid, M. M., Kamal, M., Paiva‐Santos, A. C., Alsaweed, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116376 · Cited by 44 · see citing works

Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model

Aso, E., Andrés‐Benito, P., & Ferrer, I. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.007 · Cited by 42 · see citing works

Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies

Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 42 · see citing works

Forsythiaside prevents β-amyloid-induced hippocampal slice injury by upregulating 2-arachidonoylglycerol via cannabinoid receptor 1-dependent NF-κB pathway

Chen, L., Yan, Y., Chen, T., Zhang, L., Gao, X., Du, C., & Du, H. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.02.008 · Cited by 40 · see citing works

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

Dolles, D., Nimczick, M., Scheiner, M., Ramler, J., Stadtmüller, P., Sawatzky, E., Drakopoulos, A., Sotriffer, C., Wittmann, H., Straßer, A., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500418 · Cited by 39 · see citing works

The role of endocannabinoid pathway in the neuropathology of Alzheimer’s disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer’s disease?

Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 39 · see citing works

Synthetic cannabinoids reduce the inflammatory activity of microglia and subsequently improve neuronal survival in vitro

Young, A. P., & Denovan‐Wright, E. M. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.06.011 · Cited by 37 · see citing works

Biological bases for a possible effect of cannabidiol in Parkinson’s disease

Ferreira‐Junior, N. C., Campos, A. C., Guimarães, F. S., Bel, E. A. D., Zimmermann, P. M. D. R., Brum, L., Hallak, J. E. C., Crippa, J. A. S., & Zuardi, A. W. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0460 · Cited by 42 · see citing works

Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

Abd‐Nikfarjam, B., Dolati‐Somarin, A., Rahimi, V. B., & Askari, V. R. (2023) · BioFactors · doi:10.1002/biof.1936 · Cited by 37 · see citing works

Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases

Franco, G. D. R. R., Smid, S. D., & Viegas, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200720172624 · Cited by 36 · see citing works

Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands

Gado, F., Ferrisi, R., Polini, B., Mohamed, K. A., Ricardi, C., Lucarini, E., Carpi, S., Domenichini, F., Stevenson, L., Rapposelli, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00582 · Cited by 35 · see citing works

Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?

Viana, M. D. B., de Aquino, P. E. A., Estadella, D., Ribeiro, D. A., & Viana, G. S. D. B. (2022) · Medical Cannabis and Cannabinoids · doi:10.1159/000527335 · Cited by 37 · see citing works

Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies

Veiga, M., Azevedo‐Silva, J., & Fernandes, J. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020155 · Cited by 35 · see citing works

Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders

Estrada, J. A., & Contreras, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200217140255 · Cited by 32 · see citing works

Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions

Behl, T., Kaur, G., BUNGAU, S. G., Jhanji, R., Kumar, A., Mehta, V., Zengin, G., Brata, R. D., Hassan, S. S. U., & Frățilă, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176235 · Cited by 34 · see citing works

G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases

Guerram, M., Zhang, L., & Jiang, Z. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.09.005 · Cited by 32 · see citing works

Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review

Pugazhendhi, A., Suganthy, N., Chau, T. P., Sharma, A. K., Unpaprom, Y., Ramaraj, R., Karuppusamy, I., & Brindhadevi, K. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.08.025 · Cited by 32 · see citing works

Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer’s Disease: Potential and Challenges

Jain, S., Singh, R., Paliwal, S., & Sharma, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230511122435 · Cited by 31 · see citing works

Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model

Chesworth, R., Cheng, D., Staub, C., & Karl, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.931384 · Cited by 29 · see citing works

Inflammation and oxidative stress are key mediators in AKB48-induced neurotoxicity in vitro

Öztaş, E., Abudayyak, M., Çeliksöz, M., & Özhan, G. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.12.005 · Cited by 28 · see citing works

Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia

Minamihata, T., Takano, K., Moriyama, M., & Nakamura, Y. (2020) · Inflammation · doi:10.1007/s10753-020-01271-4 · Cited by 27 · see citing works

Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review

Figura, M., Koziorowski, D., & Sławek, J. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0004 · Cited by 26 · see citing works

Impact of the Cannabinoid System in Alzheimer's Disease

Li, S., Huang, Y.-B., Yu, L., Ji, X.-Y., & Wu, J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201091006 · Cited by 16 · see citing works

Chronic pain in Alzheimer's disease: Endocannabinoid system

Blanton, H. L., Reddy, P. H., & Benamar, K. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114287 · Cited by 26 · see citing works

The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases

Tudorancea, I. M., Ciorpac, M., Stanciu, G. D., Caratașu, C.-C., Săcărescu, A., Ignat, B. E., Burlui, A., Rezuş, E., Creangă-Murariu, I., Alexa‐Stratulat, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102492 · Cited by 26 · see citing works

Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ 1–42 -treated mice

Zhang, R., He, Z., Jin, W., & Wang, R. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.07.030 · Cited by 24 · see citing works

Brain-specific targeted delivery of therapeutic agents using metal–organic framework-based nanomedicine

Han, Z., Yuan, M., Nguyen, N., Zhou, H.-C. “., Hubbard, J. E., & Wang, Y. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215926 · Cited by 23 · see citing works

Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

Varshini, M. S., Krishnamurthy, P. T., Shaji, N., Mani, L., & Balasubramanian, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24933 · Cited by 23 · see citing works

Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist

Polini, B., Cervetto, C., Carpi, S., Pelassa, S., Gado, F., Ferrisi, R., Bertini, S., Nieri, P., Marcoli, M., & Manera, C. (2020) · Life · doi:10.3390/life10120333 · Cited by 22 · see citing works

Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice

Wang, Y., Hong, Y., Yan, J., Brown, B., Lin, X., Zhang, X., Shen, N., Li, M., Cai, J., Gordon, M. N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052757 · Cited by 22 · see citing works

Chemical Composition and In Vitro Neuroprotective Activity of Fibre-Type Cannabis sativa L. (Hemp)

Corsi, L., Pellati, F., Brighenti, V., Plessi, N., & Benvenuti, S. (2018) · Current Bioactive Compounds · doi:10.2174/1573407214666180809124952 · Cited by 22 · see citing works

Cannabinoids for the treatment of dementia

Marković, D., Bošnjak, D., Brković, T., Jerić, M., Rubić, Ž., Vuica, A., & Puljak, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820 · Cited by 21 · see citing works

Daurichromenic Acid from the Chinese Traditional Medicinal Plant Rhododendron dauricum Inhibits Sphingomyelin Synthase and Aβ Aggregation

Deepak, H. V., Swamy, M. M. M., Murai, Y., Suga, Y., Anetai, M., Yo, T., Kuragano, M., Uwai, K., Tokuraku, K., & Monde, K. (2020) · Molecules · doi:10.3390/molecules25184077 · Cited by 21 · see citing works

Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases

Paez, J. A., & Campillo, N. E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180226095132 · Cited by 21 · see citing works

The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis

Arena, C., Gado, F., Mannelli, L. D. C., Cervetto, C., Carpi, S., Reynoso-Moreno, I., Polini, B., Vallini, E., Chicca, S., Lucarini, E., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112858 · Cited by 20 · see citing works

Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents

Marsh, D. T., & Smid, S. D. (2020) · Australian Journal of Chemistry · doi:10.1071/ch20183 · Cited by 20 · see citing works

Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer’s Disease

Dallabrida, K. G., Bender, J. M. D. O., Chade, E. S., Rodrigues, N., & Sampaio, T. B. (2024) · Brain Sciences · doi:10.3390/brainsci14060592 · Cited by 20 · see citing works

Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures

von Widdern, J. C., Hohmann, T., & Dehghani, F. (2020) · Molecules · doi:10.3390/molecules25030496 · Cited by 19 · see citing works

Effect of Cannabidiol on the Neural Glyoxalase Pathway Function and Longevity of Several C. elegans Strains Including a C. elegans Alzheimer’s Disease Model

Frandsen, J. R., & Narayanasamy, P. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00667 · Cited by 18 · see citing works

Evaluating Cannabis sativa L.'s neuroprotection potential: From bench to bedside.

Laws, J. S., & Smid, S. D. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154485 · Cited by 14 · see citing works

Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer’s Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

Bajaj, S., Zameer, S., Jain, S., Yadav, V., & Vohora, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00699 · Cited by 17 · see citing works

Germinated Brown Rice Alters Aβ(1-42) Aggregation and Modulates Alzheimer’s Disease-Related Genes in Differentiated Human SH-SY5Y Cells

Azmi, N. H., Ismail, M., Ismail, N., Imam, M. U., Alitheen, N. B., & Abdullah, M. A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/153684 · Cited by 17 · see citing works

Roles of Cannabidiol in the Treatment and Prevention of Alzheimer’s Disease by Multi-target Actions

Zhang, X. B., Li, J., Gu, J.-H., & Zeng, Y.-Q. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210331162857 · Cited by 16 · see citing works

Cannabidiol-Induced Autophagy Ameliorates Tau Protein Clearance

Vrechi, T. A. D. M., Guarache, G. C., Oliveira, R. B., Guedes, É. D. C., Erustes, A. G., Leão, A. H. F. F., Abílio, V. C., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., et al. (2025) · Neurotoxicity Research · doi:10.1007/s12640-025-00729-3 · Cited by 15 · see citing works

Cannabis sativa L. Constituents and Their Role in Neuroinflammation

Borgonetti, V., Governa, P., Montopoli, M., & Biagi, M. (2019) · Current Bioactive Compounds · doi:10.2174/1573407214666180703130525 · Cited by 15 · see citing works

Functional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation

Apweiler, M., Streyczek, J., Saliba, S. W., Collado, J. A., Hurrle, T., Gräßle, S., Muñóz, E., Normann, C., Hellwig, S., Bräse, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020959 · Cited by 13 · see citing works

The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β‐evoked neurotoxicity and changes in cell morphology in PC12 cells

Marsh, D. T., Sugiyama, A., Imai, Y., Kato, R., & Smid, S. D. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13943 · Cited by 14 · see citing works

Understanding Changes in Hippocampal Interneurons Subtypes in the Pathogenesis of Alzheimer's Disease: A Systematic Review

Reid, H. M. O., Chen-Mack, N., Snowden, T. M., & Christie, B. R. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0879 · Cited by 13 · see citing works

Phytocannabinoids in neuromodulation: From omics to epigenetics

Banerjee, S., Saha, D., Sharma, R., Jaidee, W., Puttarak, P., Chaiyakunapruk, N., & Chaoroensup, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118201 · Cited by 12 · see citing works

Impact of Cannabis-Based Medicine on Alzheimer’s Disease by Focusing on the Amyloid β-Modifications: A Systematic Study

Farkhondeh, T., Khan, H. Z., Aschner, M., Samini, F., Pourbagher‐Shahri, A. M., Aramjoo, H., Roshanravan, B., Hoyte, C. O., Mehrpour, O., & Samarghandian, S. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200708130745 · Cited by 12 · see citing works

Effects of Chronic, Low-Dose Cannabinoids, Cannabidiol, Delta-9-Tetrahydrocannabinol and a Combination of Both, on Amyloid Pathology in the 5xFAD Mouse Model of Alzheimer's Disease

Arnanz, M. A., Esteban, S. R. D. M., Martínez-Relimpio, A. M., Rimmerman, N., Zaks, N., Grande, M. T., & Romero, J. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0101 · Cited by 11 · see citing works

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review

Doumar, H., Mostafi, H. E., Elhessni, A., Touhami, M. E., & Mesfioui, A. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.011 · Cited by 9 · see citing works

N-stearoyltyrosine protects primary cortical neurons against Aβ(1–40)-induced injury through inhibiting endocannabinoid degradation

Cui, H., Yang, R., Liu, S., Fu, G., & Yang, L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.012 · Cited by 9 · see citing works

Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice

Bouter, C., Ott, F. W., Günther, D., Weig, L., Schmitz-Peiffer, F., Rozyyeva, M., Beindorff, N., & Bouter, Y. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02607-8 · Cited by 9 · see citing works

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease

Monteiro, K. L. C., Alcântara, M. G. D. S., de Aquino, T. M., & da Silva‐Júnior, E. F. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.294336 · Cited by 9 · see citing works

Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases

Sharon, N., Yarmolinsky, L., Khalfin, B., Fleisher‐Berkovich, S., & Ben‐Shabat, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126402 · Cited by 9 · see citing works

A systematic study of molecular targets of cannabidiol in Alzheimer's disease

Patil, N., Patil, K., Jain, M., Mohammed, A., Yadav, A., Dhanda, P. S., Kole, C., Dave, K., Kaushik, P., Razab, M. K. A. A., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241284464 · Cited by 8 · see citing works

Cannabidiol protects mouse hippocampal neurons from neurotoxicity induced by amyloid β-peptide25–35

Salgado, K. D. C. B., Nascimento, R. G. D. F., Coelho, P. J. F. N., Oliveira, L. A. M., & Nogueira, K. D. O. P. C. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105880 · Cited by 8 · see citing works

Cannabidiol and Neuroprotection: Evidence from Preclinical Studies

Schröder, N., da Silva, V. K., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00095-8 · Cited by 8 · see citing works

The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System

Mahdi, O., Baharuldin, M. T. H., Nor, N. H. M., Chiroma, S. M., Jagadeesan, S., & Moklas, M. A. M. (2021) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524921666210127110028 · Cited by 7 · see citing works

Medicinal cannabis extracts are neuroprotective against Aβ1–42‐mediated toxicity in vitro

Marsh, D. T., Shibuta, M., Kato, R., & Smid, S. D. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14078 · Cited by 6 · see citing works

Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease

Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6 · see citing works

P4‐067: Cannabinoid ligands directly modify beta‐amyloid fibril formation and are variably neuroprotective in vitro

Smid, S. D., & Mååg, J. L. V. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1769

Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro

Harvey, B. S., Ohlsson, K. S., Mååg, J. L. V., Musgrave, I. F., & Smid, S. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.015 · Cited by 82 · see citing works

Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures

Kreutz, S., Koch, M., Ghadban, C., Korf, H., & Dehghani, F. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.010 · Cited by 49 · see citing works

The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β‐evoked neurotoxicity and changes in cell morphology in PC12 cells

Marsh, D. T., Sugiyama, A., Imai, Y., Kato, R., & Smid, S. D. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13943 · Cited by 14 · see citing works

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & CEBALLOS, M. L. D. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 783 · see citing works